Ran Zheng
Director/Board Member presso CARIBOU BIOSCIENCES, INC.
Patrimonio netto: - $ in data 31/03/2024
Profilo
Ran Zheng is currently the Chief Executive Officer & Director at Landmark Bio PBLLC and an Independent Director at Caribou Biosciences, Inc. Previously, she worked as the Vice President-Development Supply Chain at Amgen, Inc. and as the Chief Technical Officer at Orchard Therapeutics Plc.
She received a graduate degree from the University of Minnesota and an undergraduate degree from Beijing Forestry University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 20/02/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Ran Zheng
| Società | Posizione | Inizio |
|---|---|---|
| CARIBOU BIOSCIENCES, INC. | Director/Board Member | 24/09/2021 |
| Landmark Bio PBLLC | Chief Executive Officer | 01/03/2021 |
Precedenti posizioni note di Ran Zheng
| Società | Posizione | Fine |
|---|---|---|
| ORCHARD THERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 01/02/2021 |
| AMGEN INC. | Corporate Officer/Principal | - |
Formazione di Ran Zheng
| University of Minnesota | Graduate Degree |
| Beijing Forestry University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| CARIBOU BIOSCIENCES, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
| Landmark Bio PBLLC |
- Borsa valori
- Insiders
- Ran Zheng
